Reducing Dupixent in kids with well-controlled eczema
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study looks at whether children with well-controlled eczema can safely reduce how often they take Dupixent. It aims to find the lowest effective dose to keep eczema under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 1 and 18 years old.
- Your child has been taking Dupixent for at least 12 months for eczema.
- Your child’s eczema has been well-controlled on Dupixent for the last 6 months.
- Your child is not using other prescription eczema treatments (like methotrexate, cyclosporine, or another biologic) or light therapy.
- Your child’s asthma or eosinophilic esophagitis (if they have it) must also be well-controlled.
- Your child must have health insurance and be able to keep it during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking Dupixent and receiving narrowband UVB light can improve moderate to severe atopic dermatitis (eczema). It may help people whose symptoms are significant despite usual care.
This study looks at whether people with well-controlled eczema can safely lower their dose of dupilumab (an injected medication). It aims to see if a reduced dose still keeps eczema under control.
This study looks at how well dupilumab works for children and teens with severe eczema (atopic dermatitis) even when the rash is not widespread. It aims to see if the treatment helps with itching, quality of life, and rashes in visible or sensitive areas.
This trial studies why eczema (“atopic dermatitis”) varies in severity even when people receive the medicine dupilumab. It may help doctors better predict who responds well and how to monitor treatment.
This study tests whether an oral medicine (upadacitinib) works as well as a shot (dupilumab) for children aged 2 to 12 with moderate to severe eczema. It aims to see which treatment better controls symptoms like itching and skin rashes.
This study looks at how well Dupilumab works over time for people with atopic dermatitis (eczema). It includes adults, teens, and children ages 6 and up.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.